Article Text
PDF
Statistics from Altmetric.com
METHOD
Design:
Prospective cohort study.
Setting:
European Schizophrenia Outpatient Health Outcomes study, Germany; recruitment January to December 2001.
Population:
2960 adult outpatients with DSM-IV schizophrenia either switching to or beginning a new antipsychotic (mean age 42 years; 49% male). Exclusions: IQ ⩽70, other DSM-IV schizophrenia spectrum disorders, bipolar I disorder, or psychotic disorder.
Prognostic factors:
Baseline predictors: age; gender; illness duration; symptoms (Clinical Global Impressions-Severity of Illness (CGI)-Schizophrenia scale overall severity score subscale scores). Functional predictors included occupational status, independent living and subjective wellbeing (Subjective Wellbeing Under Neuroleptic Treatment Scale (SWN-K)). Antipsychotic treatment factors included first antipsychotic, neurological side effects, and …
Footnotes
For correspondence: Martin Lambert, MD, Psychosis Early Detection and Intervention Centre, Centre for Psychosocial Medicine, Department of Psychiatry and Psychotherapy, University Medical Center Hamberg-Eppendorf, Martinistr 52, 20246 Hamburg, Germany; lambert{at}uke.uni-hamburg.de
Source of funding: Lilly Deutschland GmbH.
Footnotes
Competing interests: Dr McIntyre is a Consultant and Speaker for Astra-Zeneca, Eli Lilly, Janssen-Ortho, Organon, Wyeth, Lundbeck, GSK, Oryx, Biovail, Pfizer, Prestwick, BMS, and Shire; and has received research funding from Wyeth, GSK, Merck, Servier and Astra-Zeneca and Miss Soczynska received travel funds from Organon, Janssen Ortho.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.